Pharmaceutical Research

, 28:2657 | Cite as

From Serendipity to Mitochondria-Targeted Nanocarriers

Expert Review
First Online:
Received:
Accepted:

ABSTRACT

This review illustrates how a random observation at the laboratory bench has helped pave the way towards the development of organelle-targeted pharmaceutical nanocarriers. A fortuitous discovery in the mid 1990s involving the self-assembly of a molecule, known to accumulate inside mitochondria, has lead to the development of subcellular nanocarriers suited for the selective delivery of biologically active molecules to mitochondria inside living mammalian cells. Applications for mitochondria-specific drug and DNA delivery are described, the current state-of-the-art of mitochondrial drug targeting technology is reviewed, and its future perspectives are discussed.

KEY WORDS

apoptosis dequalinium DQAsomes gene therapy mitochondria mitochondria-specific liposomes mitochondria-targeted nanocarriers STPP liposomes triphenylphosphonium 
This is a preview of subscription content, log in to check access.

Notes

ACKNOWLEDGMENTS & DISCLOSURES

All work in the author’s laboratories has been financially supported over the years by the Mitochondrial Disease Association (Tucson, AZ), the United Mitochondrial Disease Foundation (Pittsburgh, PA), the Massachusetts Technology Transfer Center (Boston, MA), Northeastern University (Boston, MA), and Midwestern University Glendale (Glendale, AZ). The author would like to thank all his undergraduate and graduate students who have contributed to these studies. In particular, the author is appreciative for the significant contributions from his former Ph.D. students Dr. Gerard D’Souza, Dr. Sarathi Boddapati, Dr. Ching-Ming Cheng, and Dr. Eyad Katrangi.

REFERENCES

  1. 1.
    Mobacken H, Romanus M. Microvascular response to local application of dequalinium chloride. A vital microscopical study of hamster’s cheek pouch and a microangiographic study of rabbit’s ear. Br J Dermatol. 1975;92(1):63–72.PubMedGoogle Scholar
  2. 2.
    Mobacken H, Romanus M, Wengstrom C. Development of strength in dequalinium chloride-treated skin incisions in rat. Dermatologica. 1974;148(3):154–9.PubMedGoogle Scholar
  3. 3.
    Weiss MJ, Wong JR, Ha CS, Bleday R, Salem RR, Steele Jr GD, et al. Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation. Proc Natl Acad Sci USA. 1987;84(15):5444–8.PubMedGoogle Scholar
  4. 4.
    Christman JE, Miller DS, Coward P, Smith LH, Teng NN. Study of the selective cytotoxic properties of cationic, lipophilic mitochondrial-specific compounds in gynecologic malignancies. Gynecol Oncol. 1990;39(1):72–9.PubMedGoogle Scholar
  5. 5.
    Steichen JD, Weiss MJ, Elmaleh DR, Martuza RL. Enhanced in vitro uptake and retention of 3H-tetraphenylphosphonium by nervous system tumor cells. J Neurosurg. 1991;74(1):116–22.PubMedGoogle Scholar
  6. 6.
    Vercesi AE, Bernardes CF, Hoffmann ME, Gadelha FR, Docampo R. Digitonin permeabilization does not affect mitochondrial function and allows the determination of the mitochondrial membrane potential of Trypanosoma cruzi in situ. J Biol Chem. 1991;266(22):14431–4.PubMedGoogle Scholar
  7. 7.
    Horobin RW, Trapp S, Weissig V. Mitochondriotropics: a review of their mode of action, and their applications for drug and DNA delivery to mammalian mitochondria. J Control Release. 2007;121(3):125–36.PubMedGoogle Scholar
  8. 8.
    Galanakis D, Davis CA, Del Rey Herrero B, Ganellin CR, Dunn PM, Jenkinson DH. Synthesis and structure-activity relationships of dequalinium analogues as K+ channel blockers. Investigations on the role of the charged heterocycle. J Med Chem. 1995;38(4):595–606.PubMedGoogle Scholar
  9. 9.
    Zhuo S, Allison WS. Inhibition and photoinactivation of the bovine heart mitochondrial F1-ATPase by the cytotoxic agent, dequalinium. Biochem Biophys Res Commun. 1988;152(3):968–72.PubMedGoogle Scholar
  10. 10.
    Hait WN. Targeting calmodulin for the development of novel cancer chemotherapeutic agents. Anticancer Drug Des. 1987;2:139–49.PubMedGoogle Scholar
  11. 11.
    Dong Y, Berners-Price SJ, Thorburn DR, Antalis T, Dickinson J, Hurst T, et al. Serine protease inhibition and mitochondrial dysfunction associated with cisplatin resistance in human tumor cell lines: targets for therapy. Biochem Pharmacol. 1997;53(11):1673–82.PubMedGoogle Scholar
  12. 12.
    Manetta A, Emma D, Gamboa G, Liao S, Berman M, DiSaia P. Failure to enhance the in vivo killing of human ovarian carcinoma by sequential treatment with dequalinium chloride and tumor necrosis factor. Gynecol Oncol. 1993;50(1):38–44.PubMedGoogle Scholar
  13. 13.
    Bleday R, Weiss MJ, Salem RR, Wilson RE, Chen LB, Steele Jr G. Inhibition of rat colon tumor isograft growth with dequalinium chloride. Arch Surg. 1986;121(11):1272–5.PubMedGoogle Scholar
  14. 14.
    Schneider Berlin KR, Ammini CV, Rowe TC. Dequalinium induces a selective depletion of mitochondrial DNA from HeLa human cervical carcinoma cells. Exp Cell Res. 1998;245(1):137–45.PubMedGoogle Scholar
  15. 15.
    Schneider-Berlin KR, Bonilla TD, Rowe TC. Induction of petite mutants in yeast Saccharomyces cerevisiae by the anticancer drug dequalinium. Mutat Res. 2005;572(1–2):84–97.PubMedGoogle Scholar
  16. 16.
    Sancho P, Galeano E, Nieto E, Delgado MD, Garcia-Perez AI. Dequalinium induces cell death in human leukemia cells by early mitochondrial alterations which enhance ROS production. Leuk Res. 2007;31(7):969–78.PubMedGoogle Scholar
  17. 17.
    Rodrigues JR, Gamboa ND. Effect of dequalinium on the oxidative stress in Plasmodium berghei-infected erythrocytes. Parasitol Res. 2009;104(6):1491–6.PubMedGoogle Scholar
  18. 18.
    Gamboa-Vujicic G, Emma DA, Liao SY, Fuchtner C, Manetta A. Toxicity of the mitochondrial poison dequalinium chloride in a murine model system. J Pharm Sci. 1993;82(3):231–5.PubMedGoogle Scholar
  19. 19.
    Armijo Moreno M, Gutierrez Salmeron MT, Camacho Martinez F, Naranjo Sintes R, Armijo Lozano R, Garcia Mellado V, et al. Necrosis of the penis caused by dequalinim (2 findings). Actas Dermosifiliogr. 1976;67(7-8):547–52.PubMedGoogle Scholar
  20. 20.
    Weissig V, Vetro-Widenhouse TS, Rowe TC. Topoisomerase II inhibitors induce cleavage of nuclear and 35-kb plastid DNAs in the malarial parasite Plasmodium falciparum. DNA Cell Biol. 1997;16(12):1483–92.PubMedGoogle Scholar
  21. 21.
    Khor V, Yowell C, Dame JB, Rowe TC. Expression and characterization of the ATP—binding domain of a malarial Plasmodium vivax gene homologous to the B-subunit of the bacterial topoisomerase DNA gyrase. Mol Biochem Parasitol. 2005;140(1):107–17.PubMedGoogle Scholar
  22. 22.
    Rowe TC, Weissig V, Lawrence JW. Mitochondrial DNA metabolism targeting drugs. Adv Drug Deliv Rev. 2001;49(1–2):175–87.PubMedGoogle Scholar
  23. 23.
    Weissig V, Lasch J, Erdos G, Meyer HW, Rowe TC, Hughes J. DQAsomes: a novel potential drug and gene delivery system made from Dequalinium. Pharm Res. 1998;15(2):334–7.PubMedGoogle Scholar
  24. 24.
    Gulik A, Luzzati V, DeRosa M, Gambacorta A. Tetraether lipid components from a thermoacidophilic archaebacterium. Chemical structure and physical polymorphism. J Mol Biol. 1988;201(2):429–35.PubMedGoogle Scholar
  25. 25.
    Luzzati V, Gambacorta A, DeRosa M, Gulik A. Polar lipids of thermophilic prokaryotic organisms: chemical and physical structure. Annu Rev Biophys Biophys Chem. 1987;16:25–47.PubMedGoogle Scholar
  26. 26.
    De Rosa M, Gambacorta A, Gliozzi A. Structure, biosynthesis, and physicochemical properties of archaebacterial lipids. Microbiol Rev. 1986;50(1):70–80.PubMedGoogle Scholar
  27. 27.
    Weissig V, Torchilin VP. Mitochondriotropic cationic vesicles: a strategy towards mitochondrial gene therapy. Curr Pharm Biotechnol. 2000;1(4):325–46.PubMedGoogle Scholar
  28. 28.
    Weissig V, Moegel H-J, Wahab M, Lasch J. Computer simulation of DQAsomes. Proc Intl Symp Control Rel Bioact Mater. 1998;25:196–7.Google Scholar
  29. 29.
    Grinberg S, Kolot V, Linder C, Shaubi E, Kas’yanov V, Deckelbaum RJ, et al. Synthesis of novel cationic bolaamphiphiles from vernonia oil and their aggregated structures. Chem Phys Lipids. 2008;153(2):85–97.PubMedGoogle Scholar
  30. 30.
    Li Q, Mittal R, Huang L, Travis B, Sanders CR. Bolaamphiphile-class surfactants can stabilize and support the function of solubilized integral membrane proteins. Biochemistry. 2009;48(49):11606–8.PubMedGoogle Scholar
  31. 31.
    Meister A, Drescher S, Garamus VM, Karlsson G, Graf G, Dobner B, et al. Temperature-dependent self-assembly and mixing behavior of symmetrical single-chain bolaamphiphiles. Langmuir. 2008;24(12):6238–46.PubMedGoogle Scholar
  32. 32.
    Meister A, Weygand MJ, Brezesinski G, Kerth A, Drescher S, Dobner B, et al. Evidence for a reverse U-shaped conformation of single-chain bolaamphiphiles at the air-water interface. Langmuir. 2007;23(11):6063–9.PubMedGoogle Scholar
  33. 33.
    Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst. 2009;26(6):523–80.PubMedGoogle Scholar
  34. 34.
    Qiu F, Chen Y, Tang C, Zhou Q, Wang C, Shi YK, et al. De novo design of a bolaamphiphilic peptide with only natural amino acids. Macromol Biosci. 2008;8(11):1053–9.PubMedGoogle Scholar
  35. 35.
    Fuchtner C, Emma DA, Manetta A, Gamboa G, Bernstein R, Liao SY. Characterization of a human ovarian carcinoma cell line: UCI 101. Gynecol Oncol. 1993;48(2):203–9.PubMedGoogle Scholar
  36. 36.
    Weissig V, Lizano C, Ganellin CR, Torchilin VP. DNA binding cationic bolasomes with delocalized charge center: a structure-activity relationship study. STP Pharma Sci. 2001;11:91–6.Google Scholar
  37. 37.
    Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA. 1987;84(21):7413–7.PubMedGoogle Scholar
  38. 38.
    TrosdeIlarduya C, Sun Y, Duzgunes N. Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci. 2010;40(3):159–70.Google Scholar
  39. 39.
    Hart SL. Multifunctional nanocomplexes for gene transfer and gene therapy. Cell Biol Toxicol. 2010;26(1):69–81.PubMedGoogle Scholar
  40. 40.
    He CX, Tabata Y, Gao JQ. Non-viral gene delivery carrier and its three-dimensional transfection system. Int J Pharm. 2010;386(1–2):232–42.PubMedGoogle Scholar
  41. 41.
    Montier T, Benvegnu T, Jaffres PA, Yaouanc JJ, Lehn P. Progress in cationic lipid—mediated gene transfection: a series of bio-inspired lipids as an example. Curr Gene Ther. 2008;8(5):296–312.PubMedGoogle Scholar
  42. 42.
    Ma B, Zhang S, Jiang H, Zhao B, Lv H. Lipoplex morphologies and their influences on transfection efficiency in gene delivery. J Control Release. 2007;123(3):184–94.PubMedGoogle Scholar
  43. 43.
    Duguid JG, Durland RH. DNA packaging in non-viral systems. In: Rolland A, editor. Advanced gene delivery. Amsterdam: Harwood Academic; 1999. p. 45–63.Google Scholar
  44. 44.
    Sternberg B, Sorgi FL, Huang L. New structures in complex formation between DNA and cationic liposomes visualized by freeze-fracture electron microscopy. FEBS Lett. 1994;356(2–3):361–6.PubMedGoogle Scholar
  45. 45.
    Lasch J, Meye A, Taubert H, Koelsch R, Mansa-ard J, Weissig V. Dequalinium vesicles form stable complexes with plasmid DNA which are protected from DNase attack. Biol Chem. 1999;380(6):647–52.PubMedGoogle Scholar
  46. 46.
    Xu Y, Szoka Jr FC. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry. 1996;35(18):5616–23.PubMedGoogle Scholar
  47. 47.
    Weissig V, Torchilin VP. Towards mitochondrial gene therapy: DQAsomes as a strategy. J Drug Target. 2001;9(1):1–13.PubMedGoogle Scholar
  48. 48.
    Weissig V, D’Souza GGM. Cationic mitochondriotropic vesicles for DNA delivery to mitochondria. Mol Ther. 2004;9:S259.Google Scholar
  49. 49.
    Therapy ASfG. KEYWORD INDEX. Molecular Therapy 2004;9:S425–35.Google Scholar
  50. 50.
    Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza AM, et al. Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy. Science. 1988;242(4884):1427–30.PubMedGoogle Scholar
  51. 51.
    Holt IJ, Harding AE, Morgan-Hughes JA. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature. 1988;331(6158):717–9.PubMedGoogle Scholar
  52. 52.
    Tuppen HA, Blakely EL, Turnbull DM, Taylor RW. Mitochondrial DNA mutations and human disease. Biochim Biophys Acta. 2010;1797(2):113–28.PubMedGoogle Scholar
  53. 53.
    Naviaux RK. Developing a systematic approach to the diagnosis and classification of mitochondrial disease. Mitochondrion. 2004;4(5–6):351–61.PubMedGoogle Scholar
  54. 54.
    Claros MG, Perea J, Jacq C. Allotopic expression of yeast mitochondrial maturase to study mitochondrial import of hydrophobic proteins. Methods Enzymol. 1996;264:389–403.PubMedGoogle Scholar
  55. 55.
    Gray RE, Law RH, Devenish RJ, Nagley P. Allotopic expression of mitochondrial ATP synthase genes in nucleus of Saccharomyces cerevisiae. Methods Enzymol. 1996;264:369–89.PubMedGoogle Scholar
  56. 56.
    Weissig V, Torchilin VP. Cationic bolasomes with delocalized charge centers as mitochondria-specific DNA delivery systems. Adv Drug Deliv Rev. 2001;49(1–2):127–49.PubMedGoogle Scholar
  57. 57.
    Zullo SJ, Parks WT, Chloupkova M, Wei B, Weiner H, Fenton WA, et al. Stable transformation of CHO Cells and human NARP cybrids confers oligomycin resistance (oli(r)) following transfer of a mitochondrial DNA-encoded oli(r) ATPase6 gene to the nuclear genome: a model system for mtDNA gene therapy. Rejuvenation Res. 2005;8(1):18–28.PubMedGoogle Scholar
  58. 58.
    Manfredi G, Fu J, Ojaimi J, Sadlock JE, Kwong JQ, Guy J, et al. Rescue of a deficiency in ATP synthesis by transfer of MTATP6, a mitochondrial DNA-encoded gene, to the nucleus. Nat Genet. 2002;30(4):394–9.PubMedGoogle Scholar
  59. 59.
    Oca-Cossio J, Kenyon L, Hao H, Moraes CT. Limitations of allotopic expression of mitochondrial genes in mammalian cells. Genetics. 2003;165(2):707–20.PubMedGoogle Scholar
  60. 60.
    de Grey AD. Mitochondrial gene therapy: an arena for the biomedical use of inteins. Trends Biotechnol. 2000;18(9):394–9.PubMedGoogle Scholar
  61. 61.
    Figueroa-Martinez F, Vazquez-Acevedo M, Cortes-Hernandez P, Garcia-Trejo JJ, Davidson E, King MP, et al. What limits the allotopic expression of nucleus-encoded mitochondrial genes? The case of the chimeric Cox3 and Atp6 genes. Mitochondrion. 2011;11(1):147–54.PubMedGoogle Scholar
  62. 62.
    Perales-Clemente E, Fernandez-Silva P, Acin-Perez R, Perez-Martos A, Enriquez JA. Allotopic expression of mitochondrial-encoded genes in mammals: achieved goal, undemonstrated mechanism or impossible task? Nucleic Acids Res. 2011;39(1):225–34.PubMedGoogle Scholar
  63. 63.
    Yoon YG, Yang YW, Koob MD. PCR-based cloning of the complete mouse mitochondrial genome and stable engineering in Escherichia coli. Biotechnol Lett. 2009;31(11):1671–6.PubMedGoogle Scholar
  64. 64.
    Yonemura I, Nakada K, Sato A, Hayashi J, Fujita K, Kaneko S, et al. Direct cloning of full-length mouse mitochondrial DNA using a Bacillus subtilis genome vector. Gene. 2007;391(1–2):171–7.PubMedGoogle Scholar
  65. 65.
    Bigger B, Tolmachov O, Collombet JM, Coutelle C. Introduction of chloramphenicol resistance into the modified mouse mitochondrial genome: cloning of unstable sequences by passage through yeast. Anal Biochem. 2000;277(2):236–42.PubMedGoogle Scholar
  66. 66.
    Bigger BW, Coutelle C. Trial and error: how the unclonable human mitochondrial genome was cloned in yeast. Pharm Res. 2011;IN PRESS.Google Scholar
  67. 67.
    Gibson DG, Glass JI, Lartigue C, Noskov VN, Chuang RY, Algire MA, et al. Creation of a bacterial cell controlled by a chemically synthesized genome. Science. 2010;329(5987):52–6.PubMedGoogle Scholar
  68. 68.
    Koulintchenko M, Temperley RJ, Mason PA, Dietrich A, Lightowlers RN. Natural competence of mammalian mitochondria allows the molecular investigation of mitochondrial gene expression. Hum Mol Genet. 2006;15(1):143–54.PubMedGoogle Scholar
  69. 69.
    Weissig V, Seibel P, Seibel M, Torchilin VP. Binding and release of DNA-peptide conjugates by cationic mitochondriotropic vesicles (DQAsomes). Proc Intl Symp Control Rel Bioact Mater. 2001;28:850–1.Google Scholar
  70. 70.
    Weissig V, Lizano C, Torchilin VP. Selective DNA release from DQAsome/DNA complexes at mitochondria-like membranes. Drug Deliv. 2000;7(1):1–5.PubMedGoogle Scholar
  71. 71.
    Weissig V, D’Souza GG, Torchilin VP. DQAsome/DNA complexes release DNA upon contact with isolated mouse liver mitochondria. J Control Release. 2001;75(3):401–8.PubMedGoogle Scholar
  72. 72.
    D’Souza GG, Rammohan R, Cheng SM, Torchilin VP, Weissig V. DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. J Control Release. 2003;92(1–2):189–97.PubMedGoogle Scholar
  73. 73.
    Katrangi E, D’Souza G, Boddapati SV, Kulawiec M, Singh KK, Bigger B, et al. Xenogenic transfer of isolated murine mitochondria into human rho0 cells can improve respiratory function. Rejuvenation Res. 2007;10(4):561–70.PubMedGoogle Scholar
  74. 74.
    Vaidya B, Mishra N, Dube D, Tiwari S, Vyas SP. Targeted nucleic acid delivery to mitochondria. Curr Gene Ther. 2009;9(6):475–86.PubMedGoogle Scholar
  75. 75.
    Yoon YG, Koob MD, Yoo YH. Re-engineering the mitochondrial genomes in mammalian cells. Anat Cell Biol. 2010;43(2):97–109.PubMedGoogle Scholar
  76. 76.
    Lyrawati D, Trounson A, Cram D. Expression of GFP in the mitochondrial compartment using DQAsome-mediated delivery of an artificial mini-mitochondrial genome. Pharm Res. 2011;IN PRESS.Google Scholar
  77. 77.
    Lechardeur D, Lukacs GL. Intracellular barriers to non-viral gene transfer. Curr Gene Ther. 2002;2(2):183–94.PubMedGoogle Scholar
  78. 78.
    Duvvuri M, Feng W, Mathis A, Krise JP. A cell fractionation approach for the quantitative analysis of subcellular drug disposition. Pharm Res. 2004;21(1):26–32.PubMedGoogle Scholar
  79. 79.
    Duvvuri M, Gong Y, Chatterji D, Krise JP. Weak base permeability characteristics influence the intracellular sequestration site in the multidrug-resistant human leukemic cell line HL-60. J Biol Chem. 2004;279(31):32367–72.PubMedGoogle Scholar
  80. 80.
    Horobin RW. Uptake, distribution and accumulation of dyes and fluorescent probes within living cells: a structure-activity modelling approach. Adv Colour Sci Technol. 2001;4:101–7.Google Scholar
  81. 81.
    Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281(5381):1309–12.PubMedGoogle Scholar
  82. 82.
    Skulachev VP. Why are mitochondria involved in apoptosis? Permeability transition pores and apoptosis as selective mechanisms to eliminate superoxide-producing mitochondria and cell. FEBS Lett. 1996;397(1):7–10.PubMedGoogle Scholar
  83. 83.
    Chen G, Wang F, Trachootham D, Huang P. Preferential killing of cancer cells with mitochondrial dysfunction by natural compounds. Mitochondrion. 2010;10(6):614–25.PubMedGoogle Scholar
  84. 84.
    Biasutto L, Dong LF, Zoratti M, Neuzil J. Mitochondrially targeted anti-cancer agents. Mitochondrion. 2010;10(6):670–81.PubMedGoogle Scholar
  85. 85.
    Ralph SJ, Rodriguez-Enriquez S, Neuzil J, Moreno-Sanchez R. Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Mol Aspects Med. 2010;31(1):29–59.PubMedGoogle Scholar
  86. 86.
    Guchelaar HJ, Vermes A, Vermes I, Haanen C. Apoptosis: molecular mechanisms and implications for cancer chemotherapy. Pharm World Sci. 1997;19(3):119–25.PubMedGoogle Scholar
  87. 87.
    Decaudin D, Marzo I, Brenner C, Kroemer G. Mitochondria in chemotherapy-induced apoptosis: a prospective novel target of cancer therapy (review). Int J Oncol. 1998;12(1):141–52.PubMedGoogle Scholar
  88. 88.
    Andre N, Braguer D, Brasseur G, Goncalves A, Lemesle-Meunier D, Guise S, et al. Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells’. Cancer Res. 2000;60(19):5349–53.PubMedGoogle Scholar
  89. 89.
    Cheng SM, Pabba S, Torchilin VP, Fowle W, Kimpfler A, Schubert, et al. Towards mitochondria-specific delivery of apoptosis-inducing agents: DQAsomal incorporated paclitaxel. J Drug Del Sci Tech. 2005;15(1):81–6.Google Scholar
  90. 90.
    D’Souza GG, Cheng SM, Boddapati SV, Horobin RW, Weissig V. Nanocarrier-assisted sub-cellular targeting to the site of mitochondria improves the pro-apoptotic activity of paclitaxel. J Drug Target. 2008;16(7):578–85.PubMedGoogle Scholar
  91. 91.
    Vaidya B, Paliwal R, Rai S, Khatri K, Goyal AK, Mishra N, et al. Cell-selective mitochondrial targeting: a new approach for cancer therapy. Cancer Ther. 2009;7:141–8.Google Scholar
  92. 92.
    Zhang Y, Li RJ, Ying X, Tian W, Yao HJ, Men Y, et al. Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer. Mol Pharm. 2011;8(1):162–75.PubMedGoogle Scholar
  93. 93.
    Weissig V, Lizano C, Torchilin VP. Micellar delivery system for dequalinium—A lipophilic cationic drug with anticarcinoma activity. J Liposome Res. 1998;8:391–400.Google Scholar
  94. 94.
    Murphy MP, Smith RA. Drug delivery to mitochondria: the key to mitochondrial medicine. Adv Drug Deliv Rev. 2000;41(2):235–50.PubMedGoogle Scholar
  95. 95.
    Smith RA, Porteous CM, Coulter CV, Murphy MP. Selective targeting of an antioxidant to mitochondria. Eur J Biochem. 1999;263(3):709–16.PubMedGoogle Scholar
  96. 96.
    Boddapati SV, Tongcharoensirikul P, Hanson RN, D’Souza GG, Torchilin VP, Weissig V. Mitochondriotropic liposomes. J Liposome Res. 2005;15(1–2):49–58.PubMedGoogle Scholar
  97. 97.
    Schmidt MF. Fatty acid binding: a new kind of posttranslational modification of membrane proteins. Curr Top Microbiol Immunol. 1983;102:101–29.PubMedGoogle Scholar
  98. 98.
    Magee AI, Schlesinger MJ. Fatty acid acylation of eucaryotic cell membrane proteins. Biochim Biophys Acta. 1982;694(3):279–89.PubMedGoogle Scholar
  99. 99.
    Schlesinger MJ, Magee AI. Fatty Acid acylation of membrane proteins. Biophys J. 1982;37(1):126–7.PubMedGoogle Scholar
  100. 100.
    Weissig V, Lasch J, Klibanov AL, Torchilin VP. A new hydrophobic anchor for the attachment of proteins to liposomal membranes. FEBS Lett. 1986;202(1):86–90.PubMedGoogle Scholar
  101. 101.
    Weissig V, Lasch J, Gregoriadis G. Covalent coupling of sugars to liposomes. Biochim Biophys Acta. 1989;1003(1):54–7.PubMedGoogle Scholar
  102. 102.
    Weissig V, Gregoriadis G. Coupling of aminogroup bearing ligands to liposomes. In: Gregoriadis G, editor. Liposome technology. Boca Raton: CRC; 1992. p. 231–48.Google Scholar
  103. 103.
    Torchilin VP, Weissig V, Martin FJ, Heath TD, News RRC. Surface modification of liposomes. In: Torchilin VP, Weissig V, editors. Liposomes—A practical approach. 2nd ed. Oxford: Oxford University Press; 2003. p. 193–229.Google Scholar
  104. 104.
    Boddapati SV, D’Souza GG, Erdogan S, Torchilin VP, Weissig V. Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett. 2008;8(8):2559–63.PubMedGoogle Scholar
  105. 105.
    Martin B, Sainlos M, Aissaoui A, Oudrhiri N, Hauchecorne M, Vigneron JP, et al. The design of cationic lipids for gene delivery. Curr Pharm Des. 2005;11(3):375–94.PubMedGoogle Scholar
  106. 106.
    Nicolazzi C, Garinot M, Mignet N, Scherman D, Bessodes M. Cationic lipids for transfection. Curr Med Chem. 2003;10(14):1263–77.PubMedGoogle Scholar
  107. 107.
    Hirko A, Tang F, Hughes JA. Cationic lipid vectors for plasmid DNA delivery. Curr Med Chem. 2003;10(14):1185–93.PubMedGoogle Scholar
  108. 108.
    Schatzlein AG. Non-viral vectors in cancer gene therapy: principles and progress. Anticancer Drugs. 2001;12(4):275–304.PubMedGoogle Scholar
  109. 109.
    Kim CK, Haider KH, Lim SJ. Gene medicine: a new field of molecular medicine. Arch Pharm Res. 2001;24(1):1–15.PubMedGoogle Scholar
  110. 110.
    Siskind LJ, Colombini M. The lipids C2- and C16-ceramide form large stable channels. Implications for apoptosis. J Biol Chem. 2000;275(49):38640–4.PubMedGoogle Scholar
  111. 111.
    Siskind LJ. Mitochondrial ceramide and the induction of apoptosis. J Bioenerg Biomembr. 2005;37(3):143–53.PubMedGoogle Scholar
  112. 112.
    Siskind LJ, Feinstein L, Yu T, Davis JS, Jones D, Choi J, et al. Anti-apoptotic Bcl-2 family proteins disassemble ceramide channels. J Biol Chem. 2008;283(11):6622–30.PubMedGoogle Scholar
  113. 113.
    Stover TC, Sharma A, Robertson GP, Kester M. Systemic delivery of liposomal short—chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res. 2005;11(9):3465–74.PubMedGoogle Scholar
  114. 114.
    Patel NR, Hatziantoniou S, Georgopoulos A, Demetzos C, Torchilin VP, Weissig V, et al. Mitochondria-targeted liposomes improve the apoptotic and cytotoxic action of sclareol. J Liposome Res. 2010;20(3):244–9.PubMedGoogle Scholar
  115. 115.
    Dimas K, Hatziantoniou S, Tseleni S, Khan H, Georgopoulos A, Alevizopoulos K, et al. Sclareol induces apoptosis in human HCT116 colon cancer cells in vitro and suppression of HCT116 tumor growth in immunodeficient mice. Apoptosis. 2007;12(4):685–94.PubMedGoogle Scholar
  116. 116.
    Dimas K, Demetzos C, Vaos V, Ioannidis P, Trangas T. Labdane type diterpenes down—regulate the expression of c-Myc protein, but not of Bcl-2, in human leukemia T-cells undergoing apoptosis. Leuk Res. 2001;25(6):449–54.PubMedGoogle Scholar
  117. 117.
    Dimas K, Kokkinopoulos D, Demetzos C, Vaos B, Marselos M, Malamas M, et al. The effect of sclareol on growth and cell cycle progression of human leukemic cell lines. Leuk Res. 1999;23(3):217–34.PubMedGoogle Scholar
  118. 118.
    Paradissis A, Hatziantoniou S, Georgopoulos A, Psarra AM, Dimas K, Demetzos C. Liposomes modify the subcellular distribution of sclareol uptake by HCT-116 cancer cell lines. Biomed Pharmacother. 2007;61(2–3):120–4.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Midwestern University College of Pharmacy GlendaleGlendaleUSA

Personalised recommendations